CIM
RYTM icon

CIM Investment Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

CIM Investment Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Hold
2,993
– – 0.07% 214
2025
Q4 		$320K Hold
2,993
– – 0.08% 175
2025
Q3 		$302K Buy
+2,993
New +$278K 0.08% 181

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CIM Investment Management's RYTM Position: Q1 2026 in Review

CIM Investment Management held its Rhythm Pharmaceuticals (RYTM) position steady in Q1 2026 at 2,993 shares worth $260K. The position accounts for 0.07% of the portfolio, ranked #214.

CIM Investment Management first reported a position in RYTM in Q3 2025 and has held it in 3 quarters since. The position peaked at $320K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • CIM Investment Management held 2,993 shares of Rhythm Pharmaceuticals worth $260K as of Q1 2026.
  • CIM Investment Management left its Rhythm Pharmaceuticals share count unchanged in Q1 2026.
  • Rhythm Pharmaceuticals made up 0.07% of CIM Investment Management's portfolio in Q1 2026, its #214 holding.
  • CIM Investment Management first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • CIM Investment Management's Rhythm Pharmaceuticals position peaked at $320K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.